vs
Side-by-side financial comparison of IMAX CORP (IMAX) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
IMAX CORP is the larger business by last-quarter revenue ($125.2M vs $86.8M, roughly 1.4× IOVANCE BIOTHERAPEUTICS, INC.). On growth, IMAX CORP posted the faster year-over-year revenue change (35.1% vs 17.7%). IMAX CORP produced more free cash flow last quarter ($28.0M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 25.8%).
IMAX Corporation is a Canadian production theatre company which designs and manufactures IMAX cameras and projection systems as well as performing film development, production, post-production and distribution to IMAX-affiliated theatres worldwide. Founded in Montreal in 1967, it has headquarters in the Toronto area, and operations in New York City and Los Angeles.
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
IMAX vs IOVA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $125.2M | $86.8M |
| Net Profit | $637.0K | — |
| Gross Margin | 57.6% | 67.4% |
| Operating Margin | 19.3% | -84.7% |
| Net Margin | 0.5% | — |
| Revenue YoY | 35.1% | 17.7% |
| Net Profit YoY | -88.0% | — |
| EPS (diluted) | $0.02 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $125.2M | $86.8M | ||
| Q3 25 | $106.7M | $67.5M | ||
| Q2 25 | $91.7M | $60.0M | ||
| Q1 25 | $86.7M | $49.3M | ||
| Q4 24 | $92.7M | $73.7M | ||
| Q3 24 | $91.5M | $58.6M | ||
| Q2 24 | $89.0M | $31.1M | ||
| Q1 24 | $79.1M | $715.0K |
| Q4 25 | $637.0K | — | ||
| Q3 25 | $20.7M | $-91.3M | ||
| Q2 25 | $11.3M | $-111.7M | ||
| Q1 25 | $2.3M | $-116.2M | ||
| Q4 24 | $5.3M | — | ||
| Q3 24 | $13.9M | $-83.5M | ||
| Q2 24 | $3.6M | $-97.1M | ||
| Q1 24 | $3.3M | $-113.0M |
| Q4 25 | 57.6% | 67.4% | ||
| Q3 25 | 63.1% | 43.0% | ||
| Q2 25 | 58.5% | 5.5% | ||
| Q1 25 | 61.4% | -0.8% | ||
| Q4 24 | 52.2% | 68.7% | ||
| Q3 24 | 55.8% | 46.2% | ||
| Q2 24 | 49.4% | -0.8% | ||
| Q1 24 | 59.3% | — |
| Q4 25 | 19.3% | -84.7% | ||
| Q3 25 | 27.2% | -140.7% | ||
| Q2 25 | 15.6% | -189.8% | ||
| Q1 25 | 19.3% | -245.8% | ||
| Q4 24 | 10.3% | -117.5% | ||
| Q3 24 | 21.2% | -152.1% | ||
| Q2 24 | 3.2% | -327.6% | ||
| Q1 24 | 15.3% | -16464.6% |
| Q4 25 | 0.5% | — | ||
| Q3 25 | 19.4% | -135.3% | ||
| Q2 25 | 12.3% | -186.2% | ||
| Q1 25 | 2.7% | -235.5% | ||
| Q4 24 | 5.7% | — | ||
| Q3 24 | 15.2% | -142.7% | ||
| Q2 24 | 4.0% | -312.2% | ||
| Q1 24 | 4.1% | -15800.8% |
| Q4 25 | $0.02 | — | ||
| Q3 25 | $0.37 | — | ||
| Q2 25 | $0.20 | $-0.33 | ||
| Q1 25 | $0.04 | $-0.36 | ||
| Q4 24 | $0.09 | $-0.24 | ||
| Q3 24 | $0.26 | $-0.28 | ||
| Q2 24 | $0.07 | $-0.34 | ||
| Q1 24 | $0.06 | $-0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $151.2M | $297.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $337.9M | $698.6M |
| Total Assets | $894.0M | $913.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $151.2M | $297.0M | ||
| Q3 25 | $143.1M | $300.8M | ||
| Q2 25 | $109.3M | $301.2M | ||
| Q1 25 | $97.1M | $359.7M | ||
| Q4 24 | $100.6M | $323.8M | ||
| Q3 24 | $104.5M | $397.5M | ||
| Q2 24 | $91.6M | $412.5M | ||
| Q1 24 | $81.0M | $356.2M |
| Q4 25 | $337.9M | $698.6M | ||
| Q3 25 | $349.5M | $702.3M | ||
| Q2 25 | $320.4M | $698.5M | ||
| Q1 25 | $299.5M | $767.9M | ||
| Q4 24 | $299.5M | $710.4M | ||
| Q3 24 | $289.4M | $773.5M | ||
| Q2 24 | $267.2M | $768.5M | ||
| Q1 24 | $258.8M | $680.0M |
| Q4 25 | $894.0M | $913.2M | ||
| Q3 25 | $889.6M | $904.9M | ||
| Q2 25 | $868.6M | $907.4M | ||
| Q1 25 | $848.3M | $966.7M | ||
| Q4 24 | $830.4M | $910.4M | ||
| Q3 24 | $847.6M | $991.1M | ||
| Q2 24 | $827.4M | $964.3M | ||
| Q1 24 | $824.1M | $869.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $29.4M | $-52.6M |
| Free Cash FlowOCF − Capex | $28.0M | $-61.9M |
| FCF MarginFCF / Revenue | 22.3% | -71.3% |
| Capex IntensityCapex / Revenue | 1.1% | 10.7% |
| Cash ConversionOCF / Net Profit | 46.11× | — |
| TTM Free Cash FlowTrailing 4 quarters | $118.9M | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $29.4M | $-52.6M | ||
| Q3 25 | $67.5M | $-78.7M | ||
| Q2 25 | $23.2M | $-67.4M | ||
| Q1 25 | $7.0M | $-103.7M | ||
| Q4 24 | $11.5M | $-73.3M | ||
| Q3 24 | $35.3M | $-59.0M | ||
| Q2 24 | $35.0M | $-98.4M | ||
| Q1 24 | $-11.0M | $-122.3M |
| Q4 25 | $28.0M | $-61.9M | ||
| Q3 25 | $64.8M | $-89.5M | ||
| Q2 25 | $20.9M | $-74.9M | ||
| Q1 25 | $5.3M | $-109.9M | ||
| Q4 24 | $6.9M | $-77.5M | ||
| Q3 24 | $34.2M | $-61.3M | ||
| Q2 24 | $33.5M | $-98.9M | ||
| Q1 24 | $-12.1M | $-126.5M |
| Q4 25 | 22.3% | -71.3% | ||
| Q3 25 | 60.7% | -132.7% | ||
| Q2 25 | 22.8% | -124.9% | ||
| Q1 25 | 6.1% | -222.8% | ||
| Q4 24 | 7.4% | -105.1% | ||
| Q3 24 | 37.3% | -104.6% | ||
| Q2 24 | 37.6% | -317.9% | ||
| Q1 24 | -15.3% | -17685.3% |
| Q4 25 | 1.1% | 10.7% | ||
| Q3 25 | 2.6% | 16.1% | ||
| Q2 25 | 2.6% | 12.4% | ||
| Q1 25 | 1.9% | 12.6% | ||
| Q4 24 | 5.0% | 5.7% | ||
| Q3 24 | 1.2% | 3.9% | ||
| Q2 24 | 1.8% | 1.4% | ||
| Q1 24 | 1.4% | 583.4% |
| Q4 25 | 46.11× | — | ||
| Q3 25 | 3.27× | — | ||
| Q2 25 | 2.06× | — | ||
| Q1 25 | 2.99× | — | ||
| Q4 24 | 2.16× | — | ||
| Q3 24 | 2.54× | — | ||
| Q2 24 | 9.78× | — | ||
| Q1 24 | -3.35× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IMAX
| Technology Sales | $46.6M | 37% |
| Image Enhancement And Maintenance Services | $38.1M | 30% |
| Joint Revenue Sharing Arrangement | $20.4M | 16% |
| Maintenance | $16.3M | 13% |
| Finance Income | $2.8M | 2% |
| Other Content Solutions | $1.6M | 1% |
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
